Sumitomo subsidiary flashes new way of treating schizophrenia in PhII trial
A US-based subsidiary of Japanese pharma giant Sumitomo is touting the mid-stage results of a schizophrenia drug they say offers a new way to treat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
